MedTrace Logo

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

NCT06823167 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2026-04-15

No results posted yet for this study

Summary

IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

Conditions

Interventions

BIOLOGICAL

IM-1021

IM-1021 is an antibody-drug conjugate

Sponsors & Collaborators

  • Immunome, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2028-05-31
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06823167 on ClinicalTrials.gov